Science
We combine target selection, structural insight and translational science to find the protein–protein interactions worth drugging.
Our science
Making the undruggable Druggable
Small molecules for protein–protein interactions, a target class long treated as undruggable.
Our approach
Science. Molecules. Talent.
Rigorous research, purpose-built small molecules and a multidisciplinary team, focused on one goal: bringing protein–protein interactions within reach of medicine.
Molecules
We design small molecules for selectivity at protein interfaces, the surfaces conventional drug discovery has struggled to reach.
Molecule design
Talent
Our multidisciplinary team brings deep expertise across discovery, chemistry and development.
Careers & cultureOur platform
Target to candidate
One integrated path, from choosing the right interaction to advancing the right molecule.
-
Discovery
Target selection
We use computational and structural biology to find protein–protein interactions with clear disease relevance and a credible route to small-molecule binding.
-
Chemistry
Molecule design
Biophysical screening, fragment-based methods and structure-based design guide molecules toward selectivity at difficult interfaces.
-
Development
Translational strategy
We connect discovery data to development strategy, so promising candidates advance on evidence.
-
Collaboration
Teams and alliances
Cross-functional teams and partnerships extend what we can do, from target validation to lead optimization.
Pipeline Draft: placeholder pending confirmation
Our programs
Program details are published here as they are confirmed.
| Program | Target / Indication | Discovery | Lead optimization | IND-enabling |
|---|---|---|---|---|
| PPI-101 | Target pending Indication pending | Stage TBC | ||
| PPI-202 | Target pending Indication pending | Stage TBC | ||
| PPI-303 | Target pending Indication pending | Stage TBC | ||
-
PPI-101
Target pending · Indication pending
Stage TBC
-
PPI-202
Target pending · Indication pending
Stage TBC
-
PPI-303
Target pending · Indication pending
Stage TBC
By the numbers Draft: placeholder pending confirmation
- Pipeline progression rate
- 40%
- Compounds evaluated yearly
- 10K
- Ongoing research partnerships
- 23+
- Evidence-based decisions
- 100%
Latest news Draft: placeholder pending confirmation
From the lab and the company
-
Date TBC
Science
Headline pending
-
Date TBC
Company
Headline pending
-
Date TBC
Perspectives
Headline pending
FAQ
Frequently asked questions
Answers to common questions about our science, programs and partnering.
Contact usWhat is your scientific focus?
We discover and develop small-molecule medicines that modulate protein–protein interactions, a target class long considered undruggable.
How do you select targets?
We take a data-driven approach, combining structural biology, computational analysis and disease biology to find interactions that drive disease and can be reached by a small molecule.
What stages are your programs in? Draft: placeholder pending confirmation
Program stages will be published on our Pipeline page once confirmed.
How can I partner with you or learn more?
For partnership, investor or media inquiries, visit our Contact page. We welcome collaboration with academic, clinical and industry partners.
Partner with us
Accelerate tomorrow's therapies
Talk with our scientific team about partnering, licensing or investment. We welcome inquiries from collaborators, investors and scientific leaders.